Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Context Therapeutics to Participate in Upcoming Investor Conferences in November
-
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
-
Jianzhi Education Technology Strengthens its EdTech Capabilities with AI
-
Lloyds Bank PLC: 2024 Q3 Interim Management Statement
-
EBC Financial Group and the University of Oxford’s Department of Economics Announce WERD Episode on Macroeconomics and Climate
-
Landsbankinn hf.: Financial results of Landsbankinn for the first nine months of 2024
-
UP Fintech Announces Pricing of Follow-on Public Offering of American Depositary Shares
-
ROCKWOOL A/S – transactions in connection with share buy-back programme
-
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
-
DIOS to pursue exploration of Heberto Gold discovery, Quebec
-
MGA Entertainment Introduces Fraggle Rock: Back to the Rock Plush Line Under Little Tikes® Brand
-
ShorePoint Showcases Resilient Cyber Defenses with ISO 27001:2022 Certification
-
Modifi Biosciences Acquired by Merck
-
Manhattan Bridge Capital, Inc. Reports Third Quarter 2024 Results
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Learning Technologies Group plc
-
Chicago Atlantic Real Estate Finance Closes on $50 Million Unsecured Term Loan to Fund Deployment of New Investments
-
EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes
-
Nevada Lithium Achieves 97% Lithium and 98% Boron Recovery on High-Grade Mineralization. Engages Fluor Enterprises, Inc. to Design Flowsheet and Process Plant for Updated PEA
-
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
-
CFA Societies Canada announces 2024-2025 Board of Directors
-
Stifel Reports Third Quarter 2024 Results
-
Fidelity D & D Bancorp, Inc. Reports Third Quarter 2024 Financial Results
-
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
-
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tu
-
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
-
Siyata Mobile to Present at The ThinkEquity Conference
-
Solstice Commences Alpha IP Program at Strathy Gold Project, Abitibi Subprovince
-
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
-
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
-
Winnebago Industries Reports Fourth Quarter and Full Year Fiscal 2024 Results
-
Kaixin Holdings Announces Share Consolidation
-
Telesat awards contract to Intellian to design and supply gateway antennas for the Telesat Lightspeed network
-
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
-
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Mol
-
Omni-Lite Industries to Offer Virtual Attendance for Annual Meeting
-
Village Farms International to Report Q3/24 Results on November 7, 2024
-
ScottsMiracle-Gro Announces Timing of Fourth Quarter 2024 Financial Results and Webcast
-
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
-
Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy
-
Talen Energy to Report Third Quarter 2024 Financial Results on November 12, 2024
-
Creative Potential: New Study Reveals AI’s Role in Bridging the Gap Between Insights and Creative Impact
-
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
-
Climb Channel Solutions Launches NA Partnership with Software Management Platform Vendor, FinQuery
-
Katapult to Announce Third Quarter 2024 Financial Results on November 6, 2024
-
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
-
Dimensional Fund Advisors Ltd. : Form 8.3 - STONEX GROUP INC - Ordinary Shares
-
YieldMax™ ETFs Announces Distributions on MSTY (175.64%), AIYY (100.45%), SQY (70.37%), YMAX (67.11%), YMAG (14.96%) and Others
-
Roper Technologies announces third quarter financial results
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Keywords Studios plc

